Please try another search
MetaStat, Inc. is a pre-commercial molecular diagnostic company focused on the development and commercialization of diagnostics to provide oncologists and patients with clinically actionable information regarding the risk of systemic metastasis and adjuvant chemotherapy treatment decisions. The Company's platform technologies are based on the identification of a pathway for the development of metastatic disease in epithelial-based solid tumors. It is developing two driver-based diagnostic product lines: MetaSite Breast and MenaCalc. Its MetaSite Breast and MenaCalc diagnostic product candidates are designed for patients based on their individual risk of metastasis. The MetaSite Breast test is applicable for early stage invasive breast cancer patients. The MenaCalc platform is a tissue-based quantitative immunofluorescence (QIF) assay applicable to a range of epithelial-based cancers, including breast, lung, colorectal and prostate.
Name | Age | Since | Title |
---|---|---|---|
Jerome Bernard Zeldis | 71 | 2016 | Independent Chairman of the Board |
Paul R. Billings | 69 | 2017 | Independent Director |
Douglas A. Hamilton | 55 | 2014 | CEO, President & Director |
Renato T. Skerlj | - | 2017 | Member of Scientific & Clinical Advisory Board |
Bruce R. Zetter | - | 2015 | Member of Scientific & Clinical Advisory Board |
Frank B. Gertler | - | - | Member of Scientific & Clinical Advisory Board |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review